Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024–2028
Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases
Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early progression cannot be detected by the structural or functional changes associated with NDDs.
This study is a comprehensive analysis that explores technological advancements, industry dynamics, strategic insights, and growth opportunities in molecular diagnostics for NDDs. It captures the role of leading companies, growing start-ups, and smaller companies with innovative product portfolios and an industry presence, key drivers and restraints, and strategic partnerships. The study also delves into funding, grants, mergers and acquisitions (M&As), and commercialization efforts.
Overall, this study aims to provide insights into the evolving landscape of molecular diagnostics for NDDs and implications for healthcare innovation and patient care.
Key Questions the Study Answers:
1. What are the different molecular diagnostics for NDDs?
2. What are the main challenges and complexities in the widespread adoption of molecular diagnostics compared to imaging diagnostics?
3. What are the primary sources of biomarkers used in NDDs? Who are the key and emerging participants in terms of innovation and technology in this space?
4. How are omics technologies, smart PoC devices, and exosome-mediated diagnoses emerging as novel molecular diagnostics modalities for NDDs? How do they improve accuracy?
5. What are the strategic implications of the emerging collaborations and M&As between academia and industry participants?
6. How do patents contribute to advancements in diagnostics and therapeutics for NDDs?
7. What are the growth opportunities for molecular diagnostics for NDDs?
- Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative 8
- The Impact of the Top 3 Strategic Imperatives on Molecular
- Growth Opportunities Fuel the Growth Pipeline Engine
- Research Methodology
- Growth Opportunity Analysis
- Dementia Disease Burden Forecast for 2050
- Insights into NDD Research: Trends in Publications and Clinical Trials, 2019–2024
- NDDs: Overview and Importance of Early Diagnosis
- Segmentation
- Challenges in Early NDD Diagnosis
- Diagnostic Modalities in the NDD Landscape
- Sources of NDD Molecular Biomarkers
- Scope of Analysis
- NDD Diagnosis: Biomarker Sources, Sample Extraction, and Analytes
- Biomarker Sources: A Comparative Analysis
- Integrated Landscape of NDD Biomarkers
- Growth Generator
- Growth Drivers
- Growth Restraints
- Technology Analysis: CSF Biomarkers
- CSF-based Molecular Diagnostics to Detect NDDs
- Key Companies Developing CSF-based Molecular Diagnostics for NDDs
- Emerging Company Developing CSF-based Molecular Diagnostics for NDDs
- Key Biomarkers for Neurodiagnostics: CSF-based Biomarkers, Global, 2024
- Technology Analysis: Blood Biomarkers
- Blood-based Biomarkers in NDD Diagnosis
- Key Companies Developing Blood-based Molecular Diagnostics for NDDs
- Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs
- Key Biomarkers for Neurodiagnostics: Blood-based Biomarkers, Global, 2024
- Technology Analysis: Salivary Biomarkers
- Salivary Biomarkers: An Accessible and Painless Diagnostic Approach for NDDs
- Emerging Companies Developing Saliva-based Molecular Diagnostics for NDDs
- Technology Analysis: Urinary Biomarkers
- Urinary Biomarkers for Early Diagnosis of NDDs
- Emerging Companies Developing Urine-based Molecular Diagnostics for NDDs
- Technology Analysis: Ocular Biomarkers
- Ocular Biomarkers: A New Frontier in NDD Diagnosis
- Neurobiomarkers: Molecular Alterations in the Ocular Space
- Emerging Companies Developing Ocular-based Molecular Diagnostics for NDDs
- Technology Analysis: Skinbased Biomarkers
- Skin-based Biomarkers for NDDs
- Summary of Key Biomarkers for NDD Molecular Diagnostics
- Key Insights: Biomarker Utilization by Industry Participants in the NDD Diagnostics Space
- Molecular Biomarkers: From Bench to Clinic, Impact Analysis
- Clinical Trial Analysis
- Notable Clinical Trials in NDD Molecular Diagnostics
- European Platform for Neurodegenerative Disorders (EPND): A Collaborative Approach to Data and Sample Sharing
- Emerging Trends in NDD Molecular Diagnostics
- Databases and Biobanks: Catalysts for Biomarker Discovery in NDD Diagnosis
- Epigenetic Alterations as NDD Biomarkers
- Big Data-powered Multiomics for NDD Diagnosis
- Exosomes: A Potential Candidate for Early NDD Diagnosis
- Portable Molecular Diagnostic Devices Enabling Smart Diagnostics for NDDs
- Key Participants' Strategic Recommendations
- Synaps Dx, US
- AgenT Biotech, France
- Urvogelbio, India
- Resonant, US
- Neurodex, US
- Stakeholder Initiatives
- Notable NDD Diagnostics Collaborations and Clinical Alliances
- Recent NDD Diagnostics Mergers and Acquisitions
- Global Companies in NDD Diagnostics: Insight into Regional Adoption
- Funding Analysis
- Snapshot of Public Funding for Molecular Diagnostics of NDDs in the US, 2019–2024
- Special Focus on NIH Funding for Molecular Diagnostics of AD, 2019– 2024
- EU R&D Projects, 2019–2023
- Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2021– 2024
- Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2020– 2023
- Patent Analysis
- IP Trends in the Molecular Neurobiomarker Industry, 2019–2024
- Patents by Key Participants in the NDD Diagnostics Space, 2019–2024
- Analysis of IP Trends in the Molecular Neurobiomarker Industry, 2019–2024
- Analyst Perspectives
- Molecular Diagnostics in NDDs: Technology, Innovation, and Application Impact Analysis
- Commercial Availability of Different Molecular Diagnostic Technologies in the NDD Landscape
- Molecular Diagnosis of NDDs: A Technology Road Map
- Growth Opportunities
- Growth Opportunity 1: Smart Diagnostics at the Point of Care for NDD Detection and Management
- Growth Opportunity 2: Integrated Diagnostics for Comprehensive NDD Assessment
- Growth Opportunity 3: Exosomics and Metabolomics in the NDD Space
- Appendix
- Technology Readiness Levels (TRLs): Explanation
- Next Steps
- Benefits and Impacts of Growth Opportunities
- Next Steps
- Take the Next Step
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook